UCB PHARMA SA

🇧🇪Belgium

Country: 🇧🇪Belgium

Ownership: Public, Subsidiary

Established: 1928-01-01

Employees: 9K

Market Cap: $34.9B

Website: https://www.ucb-iberia.com/home

Clinical Trials

A Trial to Assess the Efficacy and Safety of SPM 927 (Lacosamide) in Subjects With Painful Distal Diabetic Neuropathy

Phase 3

Completed

Conditions: Diabetic Neuropathy

First Posted Date: 2005-10-13

Last Posted Date: 2014-09-22

Lead Sponsor: UCB Pharma

Target Recruit Count: 357

Registration Number: NCT00238524

Locations: 🇩🇪
Schwarz, Monheim, Germany

An Open-label Continuation Trial to Assess the Continued Efficacy and Safety of Ascending Doses of Lacosamide in Subjects With Chronic Refractory Neuropathic Pain

Phase 2

Completed

Conditions: Chronic Refractory Neuropathic Pain

Interventions: Drug: Lacosamide

First Posted Date: 2005-10-12

Last Posted Date: 2017-08-28

Lead Sponsor: UCB Pharma

Target Recruit Count: 7

Registration Number: NCT00237458

A Follow-On Trial to Assess the Long Term Safety and Efficacy of SPM 927 in Painful Distal Diabetic Neuropathy

Phase 2

Completed

Conditions: Diabetic Neuropathy

Interventions: Drug: lacosamide

First Posted Date: 2005-10-10

Last Posted Date: 2018-07-17

Lead Sponsor: UCB Pharma

Target Recruit Count: 451

Registration Number: NCT00235443

A Trial to Assess the Efficacy and Safety of SPM 927 in Subjects With Painful Distal Diabetic Neuropathy

Phase 2

Completed

Conditions: Diabetic Neuropathy

First Posted Date: 2005-10-10

Last Posted Date: 2014-09-22

Lead Sponsor: UCB Pharma

Target Recruit Count: 496

Registration Number: NCT00235469

Locations: 🇺🇸
Schwarz, RTP, North Carolina, United States

A Trial to Assess the Long-term Safety and Efficacy of Lacosamide in Subjects With Painful Diabetic Neuropathy

Phase 3

Completed

Conditions: Painful Diabetic Neuropathy

Interventions: Drug: Lacosamide

First Posted Date: 2005-09-22

Last Posted Date: 2023-07-24

Lead Sponsor: UCB Pharma

Target Recruit Count: 371

Registration Number: NCT00220337

A Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel Group Trial to Investigate the Efficacy and Safety of SPM 927 (200mg/Day and 400mg/Day) as Adjunctive Therapy in Subjects With Partial Seizures With or Without Secondary Generalization

Phase 3

Completed

Conditions: Partial Seizures With or Without Secondary Generalization

First Posted Date: 2005-09-22

Last Posted Date: 2014-09-22

Lead Sponsor: UCB Pharma

Registration Number: NCT00220415

Locations: 🇩🇪
Schwarz, Monheim, Germany

Open Label Trial to Study the Long-term Safety and Efficacy of Seletracetam for the Treatment of Epilepsy

Phase 3

Withdrawn

Conditions: Epilepsy

First Posted Date: 2005-09-15

Last Posted Date: 2012-05-28

Lead Sponsor: UCB Pharma

Registration Number: NCT00175851

Levetiracetam in the Treatment of Neuroleptic-induced Tardive Dyskinesia

Phase 2

Completed

Conditions: Dyskinesia, Medication-induced

First Posted Date: 2005-09-15

Last Posted Date: 2013-12-06

Lead Sponsor: UCB Pharma

Target Recruit Count: 70

Registration Number: NCT00175955

A Dose-ranging Study With Brivaracetam in Patients From 16 to 65 Years With Refractory Partial Onset Seizures.

Phase 2

Completed

Conditions: Epilepsy

Interventions: Other: Placebo
Drug: Brivaracetam

First Posted Date: 2005-09-15

Last Posted Date: 2018-10-02

Lead Sponsor: UCB Pharma

Target Recruit Count: 210

Registration Number: NCT00175825

Open Label Study (Everyone Who Participates Receives Drug) to Further Determine How Safe and Effective Oral Treatment of Seletracetam is in Patients With Refractory Epilepsy.

Phase 3

Withdrawn

Conditions: Epilepsy

First Posted Date: 2005-09-15

Last Posted Date: 2012-03-20

Lead Sponsor: UCB Pharma

Registration Number: NCT00175864

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy